abstract |
The present disclosure provides a biomarker for prognostic prediction of cancer immunotherapy by an immune checkpoint inhibitory drug, the biomarker being one or more selected from the group consisting of CXCL2, VEGF, CHI3L1, IFNα2, GM-CSF, and MMP2. |